Disproportionality Signal Found for Suicidality in Finasteride Users
Younger patients and those with alopecia have significant disproportionality signals for increased suicidality
Benign Prostatic Hyperplasia
Risk for T2DM Increased With Use of 5α-Reductase Inhibitors
Increased risk seen among men using dutasteride, finasteride for benign prostatic hyperplasia
Finasteride Not Tied to Increase in Prostate Cancer Mortality
Finasteride is not associated with an increased risk for death due to prostate cancer, according to a research letter published in the New England Journal of Medicine.
Bethanechol Prescribing Patterns Examined in Women With Bladder Dysfunction
While bethanechol, a cholinergic agonist, may “theoretically” improve detrusor contractility in women with underactive bladder (UAB), the evidence supporting its use is limited.
Mortality Risk Compared Among Men Receiving Drug Therapy for BPH/LUTS
Researchers conducted a retrospective matched cohort study to compare the risk of death among BPH patients treated with 5ARIs, as monotherapy or in combination with alpha-blockers, and those treated with alpha-blockers alone.
AUA Updates Castration-Resistant Prostate Cancer Clinical Guideline
“We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC,” said Michael Cookson, MD, member of the 2018 amendment panel.
AUA: Guideline on Surgical Management of BPH-Related Lower Urinary Tract Symptoms
The new guideline includes 22 recommendations focused on utilizing common surgical techniques and minimally invasive surgical therapies.
Nymox Plans to Submit NDA for Novel Benign Prostatic Hyperplasia Treatment
Fexapotide triflutate 2.5 mg was found to be safe and effective for long-term treatment of BPH.
Italian-Style Coffee Consumption May Reduce Prostate Cancer Risk
Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.
USPSTF Drafts Prostate CA Screening Recommendations
The USPSTF performed a systematic review of the existing evidence and concluded that the potential benefits and harms of prostate-specific antigen (PSA)-based screening are “closely balanced” in men aged 55-69 years.
